Sharett Institute, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FEBS J. 2013 May;280(10):2307-19. doi: 10.1111/febs.12184. Epub 2013 Mar 4.
Recent years have seen a growing body of evidence that enzymatic remodeling of heparan sulfate proteoglycans profoundly affects a variety of physiological and pathological processes, including inflammation, neovascularization, and tumor development. Heparanase is the sole mammalian endoglycosidase that cleaves heparan sulfate. Extensively studied in cancer progression and aggressiveness, heparanase was recently implicated in several inflammatory disorders as well. Although the precise mode of heparanase action in inflammatory reactions is still not completely understood, the fact that heparanase activity is mechanistically important both in malignancy and in inflammation argues that this enzyme is a candidate molecule linking inflammation and tumorigenesis in inflammation-associated cancers. Elucidation of the specific effects of heparanase in cancer development, particularly when inflammation is a causal factor, will accelerate the development of novel therapeutic/chemopreventive interventions and help to better define target patient populations in which heparanase-targeting therapies could be particularly beneficial.
近年来，越来越多的证据表明，肝素硫酸蛋白聚糖的酶促重塑深刻影响着多种生理和病理过程，包括炎症、新血管生成和肿瘤发展。肝素酶是唯一能够切割肝素硫酸的哺乳动物内切糖苷酶。肝素酶在癌症的进展和侵袭性方面得到了广泛的研究，最近也被牵连到几种炎症性疾病中。尽管肝素酶在炎症反应中的具体作用模式仍不完全清楚，但肝素酶活性在恶性肿瘤和炎症中都具有重要的机制作用，这表明该酶是将炎症与炎症相关癌症中的肿瘤发生联系起来的候选分子。阐明肝素酶在癌症发展中的具体作用，特别是当炎症是一个因果因素时，将加速新型治疗/化学预防干预措施的发展，并有助于更好地确定肝素酶靶向治疗可能特别有益的目标患者群体。
